期刊文献+

利奈唑胺在治疗难治性中枢神经系统革兰阳性球菌感染中的价值 被引量:10

Value of Linezolid in Treatment of Gram-positive Refractory Central Nervous System Infection Caused by Coccus
原文传递
导出
摘要 目的探讨利奈唑胺在治疗球菌引起的难治性中枢神经系统感染中的合理性及其价值。方法对2008年3月-2009年7月3例使用利奈唑胺治疗难治性中枢神经系统革兰阳性球菌感染的患者进行疗效观察。结果 3例患者均进行了脑脊液培养:第1例为耐甲氧西林表皮葡萄球菌(MRSE),但使用万古霉素不能控制感染;第2例为肠膜明串珠葡萄聚糖亚种,药敏对万古霉素和替考拉宁耐药,对利奈唑胺敏感;第3例最初为头状葡萄球菌,对万古霉素敏感,使用万古霉素3周后感染控制不理想,脑脊液培养出现了万古霉素耐药的屎肠球菌(VREF)。3例患者最终均使用了利奈唑胺4~6周并且得以康复出院,随诊未复发。结论利奈唑胺有良好的脑脊液的穿透率,可用于治疗中枢神经系统革兰阳性球菌感染,尤其在难治性中枢神经系统革兰阳性球菌感染中的价值更为突出,希望能够得到更多成功病例的进一步验证。 OBJECTIVE To discuss the rationality and value of Linezolid in the treatment of to treat central nervous system infection caused by Gram-positive coccus.METHODS The treatment results of three cases of central nervous system infection patients treated by using linezolid from Mar 2008 to July 2009 were obserued.RESULTS Cerebrospinal fluid(CSF)from 3 patients were cultared,the first case:methicillin-resistant Staphylococcus epidermidis(MRSE),vancomycin could not control the spread of infection.Cerebrospinal fluid(CSF)cultivation of the second case:leuconostoc mesenteroides subsp,dextranciu resistant to vancomycin and teicoplanin,sensitive to Linezolid.Cerebrospinal fluid(CSF)cultivation of the third case:S.capitis.Sensitive to vancomycin.The infection was not controlled very well by using vancomycin for three weeks and vancomycin-resistant Enterococcus faecium(VREF)was found in the CSF cultivation.The three patients finally used Linezolid for about four to six weeks and got recovery and no recurrence lately.CONCLUSION Linezolid has very good penetration ability in CSF,it can be used in the treatment of central nervous system infection caused by Gram-positive coccus.It has an out standing value in the treatment of the refractory central nervous system infection caused by coccus,hoping that it can be approved by more successful cases.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2010年第20期3207-3209,共3页 Chinese Journal of Nosocomiology
关键词 利奈唑胺 万古霉素 中枢神经系统感染 革兰阳性球菌 Linezolid vancomycin Central nervous system infection(CNS) Gram-positive coccus
  • 相关文献

参考文献5

二级参考文献11

  • 1Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy[J]. Neurology, 2006,66 (4) :595-598.
  • 2Skia J, Stefani KW. Linezolid-novel antibiotic for the treatment of Gram-positive bacterial infections[J]. Wiad Lek, 2006,59(9/10) : 727-731.
  • 3Ito W, Takeda M, Kayaba H, et al. Clinical evaluation after a notification policy of linezolid use:a case series of patients[J]. J Chemother,2009,21(1):52-57.
  • 4Wunderink,Richard G,Mendelson,etal. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus [J]. Chest,2008,134(6):200-207.
  • 5Piqrau C,Almirante B. Oxazolidinones, glycopeptides and cyclic lipopeptides[J]. Enferm Infect Microbiol Clin, 2009,27 (4) :236-246.
  • 6Wilks N. Safety and tolerance of linezolid in phase II trials [C]. Program and abstracts of the 39th Interscienee Conference on Antimierobial Agents and Chemotherapy, 1999, September 26.
  • 7Carsenti-Dellamonica, Galimand, Vandenbos. In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid : relationship with susceptibility to penicillin G or macrolides[J]. J Antimicrob Chemother,2005,56(4) : 633-642.
  • 8Athanassios T,Pillai Satish K,Gold Howard S,et al. Persistence of rRNA operon mutated copies and rapid reemergenee of linezolid resistance in Staphylococcus aureus [J]. J Antimicrob Chemother, 2007,60(3) : 649-651.
  • 9Rice LB. Antimicrobial resistance in Gram-positive bacteria [J]. Am J Infect Control,2006,34(5 Suppl 1):S64-S73.
  • 10Jankowski A, Stefanik W. Linezolid-novel antibiotic for the treatment of Gram-positive bacterial infeetions[J]. Wiad Lek,2006,59 (9-10) :727-731.

共引文献10

同被引文献97

  • 1柳国良,罗世祺,王涛.开颅术后颅内感染死亡原因及教训[J].中华神经外科杂志,1995,11(5):297-299. 被引量:86
  • 2王燕群,刘尚喜.磷脂酰丝氨酸在凋亡细胞被吞噬细胞清除中的作用[J].实用医学杂志,2006,22(13):1485-1487. 被引量:7
  • 3黄克清.神经外科学·颅内非特异性感染[M].武汉:湖北科学出版社,1998:735-743.
  • 4Tubau F, Fernandez-Roblas R, Linares J, et al. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods [J].J Antimicrob Chemother, 2001, 47 (5): 675-680.
  • 5Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses [J]. Antimicrob Agents Chemother, 2001, 45 (6): 1843-1846.
  • 6Betriu C, Redondo M, Boloix A, et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci [J]. J Antimicrob Chemother, 2001, 48 (6): 911-913.
  • 7Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents [J]. Antimicrob Agents Chemother, 1996, 40 (4): 839-845.
  • 8Cynamon MH, Klemens SP, Sharpe CA, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model [J]. Antimicrob Agents Chemother, 1999, 43 (5) : 1189-1191.
  • 9Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis[J]. Chest, 2008, 134 (1): 187-192.
  • 10Yew WW, Chau CH, Wen KH. Linezolid in the treatment of 'difficult' muhidrug-resistant tuberculosis [J]. Int J Tuberc Lung Dis, 2008, 12 (3): 345-346.

引证文献10

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部